Introduction
============

The highly successful toxin fold structure found in many venomous snake toxins also has a counterpart in mammals: prototoxins. Prototoxins are non-venomous proteins with significant similarities to elapid α-neurotoxins, most notably with regard to their cysteine-rich, three-fingered β-fold structure. The mammalian counterparts have 10--12 cysteine residues and the signature motif of 10 cysteines participating in five disulfide bonds stabilizing a β-fold structure. Prototoxins have been found in the brain, epithelium, and immune system, etc. (reviewed in [@B63]; [@B100]; [@B102]). Within the prototoxin family, there are membrane-bound GPI anchored (i.e., lynx1, lynx2, PSCA, etc.) and secreted forms of the protein (i.e., secreted ly6/uPAR related proteins SLURPs) ([@B108]; [@B1]).

Snake toxins employ functional mimicry of pathways operating in the prey. The cloning of a cDNA from the mammalian brain ([@B49]) with the cysteine-rich signature of α-neurotoxins, was suggestive that it acted on a similar molecular target as α-neurotoxins ([@B64]). Although orphan members of the mammalian superfamily had been previously identified ([@B83]), the understanding that toxins employ functional mimicry of pathways operating in the prey led to a candidate approach for investigating their function, ultimately resulting in the discovery of the initial functionally characterized prototoxin with nicotinic receptor modulatory capability, lynx1 ([@B64]; [@B40]).

Current evidence suggests snake toxins arose through gene duplication and divergence from a prototoxin-like ancestral gene ([@B1]). The presence of these two forms of prototoxins, GPI and secreted, could provide clues to understanding the evolutionary relationship of venoms and prototoxins.

In the secreted SLURP genes, a stop codon occurs prior to genomic sequence which could code for the amino acid consensus sequence for GPI-attachment, suggests that the membrane-bound forms evolved prior to the secreted forms \[i.e., secreted ly6/uPAR-related proteins (SLURPs)\] ([@B108]; [@B1]). Loss of the GPI anchor via introduction of a stop-gain mutation to generate a secreted version of the protein may be an important intermediate step in the progression from an ancestral prototoxin to the first α-neurotoxin. On the other hand, evidence of accelerated evolution in the membrane-bound form may support that notion that the GPI-anchored version evolved more recently ([@B15]). Regardless, the three-fingered fold toxin-like proteins seems to have occurred once, prior to the split between the venomous elapid snakes and the non-venomous colubrid snake family. This is supported by previous research which isolated and characterized three-fingered toxins from non-venomous colubrid snakes, demonstrating that this toxin type exhibits basal α-neurotoxic activity ([@B25]). This evidence suggests that gene recruitment occurred via a non-toxic gene in the body ([@B27]). Venom development requires a transition of genes to expression in the secretory venom gland of the snake ([@B45]), either via recruitment from a gene in the body ([@B24]) or restricted expression of a gene with wider expression, such as those in the salivary glands ([@B87]).

A few three-fingered fold protein family members have been reported to exhibit expression in the salivary gland of non-venomous species, providing possibilities for more neutral selection ([@B36]). More in-depth genomic and transcriptomic analyses of the non-venomous family will be required as more data on the snake genome become available. Although other genes, such as digestive track enzymes or ribonucleases ([@B92]), have been proposed as the ancestral gene giving rise to α-neurotoxins, separate recruitment events seem to be involved ([@B24]). Gene duplication aids in the development of venoms, as it allows for divergence in either amino acid sequence to more virulent forms or in regulatory elements to allow such changes in gene expression patterns. There is substantial evidence for gene duplication within mammalian prototoxins/non-venomous species allowing for such sub-functionalization, although the presence of clustered ly6 genes in mice, but not in humans, suggests that at least some of this duplication occurred relatively recently after the divergence of mice and humans ([@B54]). Furthermore, snake toxins have the ability to undergo accelerated evolution and selective expression in the snake venom gland ([@B26]; [@B45]). The evolutionary relationships between members of the prototoxin gene family, WTX, venomous snakes, and colubrid family members are depicted in [Figure 1](#F1){ref-type="fig"}.

![Molecular, phylogenetic, and structural analysis of the prototoxin gene family. **(A)** Bootstrap consensus tree of molecular evolutionary relationship. The percentage of replicate trees in which the associated taxa clustered together in the bootstrap test (500 replicates) are shown next to the branches. **(B)** Amino acid comparison of selected family members. Cysteines are highlighted in yellow and disulfide bridges are outlined. **(C)** Structural comparison of selected family members from the pdb database: Ws-lynx1 (2L03, green), SLURP-1 (2MUO, yellow), Weak toxin (2MJO, purple), Cobratoxin (2CTX, black).](fphar-10-00343-g001){#F1}

Introducing the Prototoxin Gene Family
======================================

The prototoxin genes are members of the ly6/uPAR superfamily, whose members adopt the receptor binding structural motif observed within elapid snake venom α-neurotoxins, due to highly conserved cysteine residues that participate in disulfide bonding ([@B56]; [@B100]; [@B102]). Among these family members are the well-studied single-domain snake venom α-neurotoxins and cardiotoxins ([@B21]; [@B83]). Three-fingered proteins are larger and generally more variable than α-neurotoxins ([@B45]). Although α-bungarotoxin (α-btx) is one of the most widely used snake toxins in neuroscience, exhibiting nearly irreversible affinity, ly6/uPAR family members have shown variability in their ability to compete with other nAChR ligands, suggesting more modest receptor affinities and potentially allosteric effects on receptor function. The expression of three-fingered proteins in the brain and body allows for biological regulation over complex nicotinic receptor-based processes across multiple systems. Members of the uPAR superfamily include CD59, lymphocyte antigen genes, ly6A-H, transforming growth factor β receptor ectodomains, and uPAR. In total, at least 2,583 sequences within seven subfamilies have been identified (PFAM database) ([@B45]). Further, the human genome encodes for at least 45 genes containing the three-fingered domain ([@B29]). Three-fingered proteins exert an influence over a wide-array of physiological processes, including proliferation, cellular differentiation, and inflammation, among others. The present review focuses on members of this family with demonstrated nAChR modulatory/binding function, with special emphasis on those expressed in the mammalian brain. Within this large superfamily, members with significant expression in the brain include lynx1 ([@B64]), lynx2/lypd1 ([@B14]; [@B106]), lypd6 ([@B12]; [@B109]), lypd6B ([@B13]), PSCA ([@B44]), and ly6h ([@B37]). SLURPs, which are expressed mostly outside the brain, have been documented in several disease states and will be also be reviewed ([@B33]; [@B102]).

Structural Features of the Prototoxin and ly6/uPar Superfamily
==============================================================

Prototoxins share structural and functional similarities to one another. Among their most notable structural features are cysteine bonds that stabilize a three-loop/three-fingered β-rich fold structure. The ly6/uPAR superfamily contains 10--12 cysteines, with one of the extra disulfide bonds in the first loop, placing this mammalian family closer to the weak toxins depicted in [Figure 1](#F1){ref-type="fig"}. NMR solution structures have greatly enhanced our understanding of this class of proteins ([@B56], [@B58], [@B60]; [@B78]). A recombinant version of lynx1 was engineered such that the sequence for GPI anchor attachment sequence was removed, water soluble lynx1 (ws-lynx1) ([@B56]). The NMR solution structure of ws-lynx1 demonstrated that the overall topology is similar to that of α-neurotoxins, although the protein is characterized by a large and mostly disordered loop III ([@B56]). The addition of a disulfide bond in loop I is common among other prototoxins and weak/unconventional snake toxins. NMR evaluation was performed for SLURP-1, synthetically derived using peptide ligation (sSLURP-1), and exhibits excellent agreement to that of rSLURP-1 in two- and three-dimensional spectral analyses ([@B17]). Unfortunately, to date, few crystal structures of prototoxins have been solved, although computational models have been developed for prototoxins and their cognate receptors ([Figure 2](#F2){ref-type="fig"}). Solution and crystal structures have been identified for members of the larger superfamily, including CD59 ([@B22]; [@B39]). CD59 as well as lypd6 and lypd6b ([@B78]) contains an α-helical domain in loop III, which is not found in the NMR structures of lynx1 ([@B56]), underscoring the notion that there is more structural variability among the three-fingered proteins of the superfamily than within three-fingered α-neurotoxins ([@B45]).

![Computational models of lynx1 interaction with nicotinic receptor subunits. **(A)** Co-model of ws-lynx1 and α4: α4 nAChR interface ([@B75]). **(B)** Co-model of ws-lynx1 and α7 nAChRs ([@B56]).](fphar-10-00343-g002){#F2}

The Cholinergic System
======================

The cholinergic system is a widespread modulatory excitatory neurotransmitter system that enables controlled regulation over multiple neural circuits. Cholinergic neurons release the endogenous neurotransmitter acetylcholine in a diffuse manner. Cholinergic projection neurons are located in the basal forebrain and brain stem, and their terminals radiate broadly throughout the central nervous system ([@B34]) onto a wide range of targets. This widespread architecture and the fact that neurotransmitter release is not confined to the synaptic cleft contribute to the modulatory capabilities of the cholinergic system. Interestingly, the activity-response relationship of the cholinergic system falls along an inverted U-shaped curve, whereby both impaired and excessive activation can exert deleterious or suboptimal effects ([@B81]). The cholinergic system operates along a gradient, with detrimental effects observed at the extremes of the range, and is therefore dependent on several regulatory mechanisms ([@B65]).

Such fine-tuning of the cholinergic system can be exerted by several factors, including the number and activity of cholinergic neurons, the level of acetylcholine release, the presence of acetylcholinesterase, and the profile of the target receptors. Cholinergic receptors can be divided into muscarinic and nicotinic receptors, which are located mainly in the peripheral and central nervous systems (PNS and CNS), respectively. In addition to acetylcholine, nicotinic receptors bind the exogenous drug of abuse, nicotine. Nicotinic AChRs exist as pentamers composed of many variations of 15 possible subunits. For instance, nicotinic receptors typically exist as heteromeric combinations of α (2--10) and β (2--4) subunits (most commonly α4β2) or as α homopentamers (α7, α9, etc.) ([@B81]; [@B3]). Receptor composition gives rise to specificity, as each combination displays distinct biophysical and pharmacological properties. In addition, differences in stoichiometry among subunits allow for differential response profiles and sensitivity to agonist.

Prototoxin proteins can form stable associations with nicotinic receptors, and the binding preference of prototoxin proteins for specific subtypes of nAChRs can further fine tune cholinergic activity by altering a selective subtype or group of receptor subtypes. Further spatial control can be imparted because prototoxins exhibit mostly non-overlapping expression patterns in the CNS ([@B65]). Indeed, multifactorial mechanisms such as receptor assembly, expression, and binding specificity contribute to the wide variety of reported effects for each family member ([@B63]).

Lynx1
=====

Lynx1 Binding and Insights Using Recombinant ws-lynx1
-----------------------------------------------------

Previous studies have revealed that a recombinant, water-soluble variant of lynx1, ws-lynx1, can inhibit α7, α4β2, and α3β2, although the functional effects are most pronounced for α4β2. The inhibitory effect is concentration-specific and non-competitive ([@B56]). Residues on loops II and III are important for the interaction ([@B57]). Although recombinant ws-lynx1 studies have been highly informative, the effects may differ from those of endogenous lynx1, since lynx1 is usually attached to the cell surface via a GPI anchor. Researchers have observed differential biological effects between cerebellum-directed transgenic mice expressing a soluble version of lynx1 (minus the amino acid sequence directing the GPI attachment) which leads to augmentations in motor learning, and those expressing normal GPI-bound lynx1 which demonstrates no effect ([@B65]). This is in accordance with the differential effects *in vitro* of ws-lynx1 which enhances ACh-evoked current amplitude vs. GPI-linked endogenous lynx1 which causes acceleration of desensitization and lowering of agonist affinity ([@B64]; [@B40]). The GPI-anchor exhibits an affinity for cholesterol-rich domains ([@B52]), and the effective concentration (EC~50~) may be higher for the membrane-bound form of lynx1.

Mechanisms Underlying the Effects of Lynx1 on Receptor Function
---------------------------------------------------------------

Lynx1 exerts its modulatory effect on the cholinergic system via direct interactions with nAChR ([@B40]; [@B73]). The effects of this interaction on receptor function are multi-factorial, influencing agonist affinity, desensitization, and recovery from desensitization. In *in vitro* studies involving *Xenopus* oocytes, cells co-expressing α4β2 nicotinic receptors and lynx1 ([@B40]) demonstrate reduced agonist sensitivity via co-expression of lynx1, as indicated by a rightward shift in the EC~50~ to acetylcholine ([@B40]). Furthermore, nAChRs exhibit a faster rate of desensitization to agonists when co-expressed with lynx1, and prolonged recovery from desensitization as assessed by dual application of agonists ([@B40]). This finding is in contrast to those of some previous reports ([@B64]), which indicated that exogenous application of lynx1 protein to oocytes expressing α4β2 nAChRs increases the amplitude of ACh currents recorded in two-electrode voltage clamp mode.

Effects of lynx1 on Nicotinic Receptor Assembly
-----------------------------------------------

Single-channel activity in α4β2 exhibits a shift toward the expression of high-conductance events and short channel open times ([@B40]). This phenotype is associated with the low-sensitivity (LS) (α4)~3~(β2)~2~ stoichiometry. Preferential interaction of lynx with α4: α4 dimers over β2:β2 dimers in the endoplasmic reticulum can help to explain the expression of mature pentamers at the plasma membrane of the LS stoichiometry (α4)~3~(β2)~2~ over the high sensitivity, HS (α4)~2~(β2)~3~ stoichiometry ([@B73]). Co-expression studies can be influenced by stoichiometry and assembly, as well as gating activity of nAChRs at the neuronal cell surface of the plasma membrane. It can be difficult to discern the relative contributions of these two effects without cleaving off the GPI anchor via PI-PLC.

[@B30] constrained the number of variables using concatemeric nAChRs, in which five subunit cDNAs are fused into a single polypeptide, fixing the receptor stoichiometry. Co-expression of lynx1 with α3β4^∗^ nAChRs (^∗^-containing) suggests a role of lynx1 in altering channel opening, while previous studies have indicated that receptor number is altered only in some isoforms, depending on the subunit identity in the fifth position ([@B30]). Lynx1 reduces (α3)~2~(β4)~3~ cell-surface expression, whereas single-channel effects were primarily responsible for reducing (α3)~3~(β4)~2~ function by enhancing closed dwell times, and by reducing conductance and the number of long bursts. Reduced cell-surface expression and increased closed dwell times accounted for the reduction in (α3)~2~(β4)~2~α5 function mediated by lynx1. These data suggest a model of lynx binding in which the ratio of lynx1 to receptor depends on the receptor isoform ([Figure 3](#F3){ref-type="fig"}). Along with expression studies of lynx1 in regions related to nicotine intake/aversion, these studies highlight the potential significance of lynx1 in nicotine addiction.

![Working model of lynx1 modulation of α3β4- and α3β4α5-nAChR function. Lynx1, depicted in green, interacts with nAChRs that contain an α3(--) subunit interface ([@B30]). D398N mutation is associated with higher nicotine intake and relapse from quit attempts in humans. The N at position 398 is the risk allele.](fphar-10-00343-g003){#F3}

Expression of Lynx1 in the CNS
------------------------------

Lynx1 is widely expressed throughout the CNS, although levels are relatively higher in the hippocampus, cortex, and cerebellum ([@B64]; [@B98]). In addition to its extensive expression in the brain, lynx1 can be found in the retina ([@B61]), lung ([@B28]), and spinal cord ([@B62]). Previous studies have noted the interesting temporal expression profile of lynx1, which can be observed beginning around postnatal week 2 or 3 in mouse models ([@B64]; [@B98]), exhibiting a close correlation with the critical period in the visual system. Changes in gene expression levels have been reported for lynx1 due to pharmacological and genetic treatment ([@B65]).

Lynx1 and Cortical Plasticity
-----------------------------

Lynx1 acts as a negative regulator of plasticity in regions such as the hippocampus and cerebellum, and the interaction of lynx1 with nicotinic receptors has been shown to alter plasticity in the adult visual and auditory cortices ([@B67]; [@B95]). Due to the experience and nAChR-dependent plasticity that occurs in the visual cortex (V1), it is a well-defined model for understanding the age-dependent molecular effects of lynx1 interactions with nAChRs. Lynx1 mRNA and protein levels increase in V1 at the end of the critical period, thereby decreasing ocular dominance plasticity ([@B67]; [@B88]). For example, the effects of lynx1 on ocular plasticity are demonstrated by an increase in responsiveness in the visual cortex in adult lynx1-null mutant KO mice during arousal, and by the discovery of a juvenile form of plasticity mediated by an interaction between lynx1 and tissue plasminogen activator ([@B67]; [@B9]). Furthermore, apical spine turnover in pyramidal neurons of layers 5 and 2/3 is doubled in the V1 of lynx1KO mice, and a selectively higher rate of loss is observed in the layer 5 of adults lacking lynx1 ([@B90]). Taken together, these results suggest that lynx1 plays a role in the structural remodeling and spine dynamics required for plasticity in the visual cortex.

Recently, lynx1 has also been linked to a reduction in auditory plasticity via associations with the α4-containing nAChR in 5-HT~3A~R-positive cells ([@B95]). In these studies, a nearly two-fold developmental increase in lynx1 expression in primary auditory cells was observed between P11 and P20, along with a decrease in nAChR sensitivity in 5-HT~3A~R cells. Furthermore, heightened nicotine sensitivity can be observed in lynx1KO mice, and such sensitivity can be attenuated using the α4 nAChR-specific antagonist DHβE ([@B95]).

Lynx1 and Associative Learning
------------------------------

Lynx1KO mice exhibit improvements in cognitive ability, for example, improved associative learning and memory behaviors ([@B66]). Contextual memory (assessed using the Morris Water Maze, passive avoidance conditioning, and contextual fear conditioning) does not significantly differ between wild-type and lynx1KO mice, suggesting a specific role of lynx1 in associative learning. To further investigate phenotypic specificity, lynx1KO mice were tested for pain sensitivity ([@B75]). Since the fear conditioning paradigm involves shock/tone pairing, this would serve as an important control test for the specificity of the learning phenotype. In one test of nociceptive signaling, the hot-plate test, lynx1KO mice exhibited no significant differences in performance when compared to their wild-type counterparts ([@B75]). Indeed, nicotine administration reduced nociceptive behavior in lynx1KO mice ([@B75]), suggesting a possible link between lynx1 and analgesia. Because dopamine levels may also influence associative learning/Pavlovian conditioning ([@B41]), researchers have investigated dopamine levels in lynx1KO mice ([@B79]). Such studies have revealed that lynx1KO mice exhibit dose-dependent decreases in dopamine levels when compared with their wild-type counterparts. Lastly, although lynx1 does seem to influence the function (but not assembly) of α6 nAChRs, as well as subsequent motor activity, such influence does not seem to extend to nicotine conditioned-place preference ([@B79]). The effects of lynx1 on α6^∗^ nAChRs seem subtle and are therefore unlikely to be a factor in associative learning as studied using these behavioral paradigms. Taken together, the effects of lynx1 are moderately specific to plasticity and associative learning.

Role of Lynx1 in Alzheimer's Disease (AD) Pathology
---------------------------------------------------

Alzheimer's disease pathology is associated with an increase in soluble β-amyloid (Aβ), a peptide cleaved from the Alzheimer's precursor protein ([@B43]; [@B97]). Recent evidence suggests that lynx1 and Aβ~1--42~ compete for binding to nAChRs. In pull-down experiments from rat cortical extracts, ws-lynx1 pulled down all nAChR subunits tested (α3-7, β2, and β4), but the only subunits in which Aβ~1--42~ led to reduced lynx1/nAChR interactions were the α3, α4, α5, and α7 nAChR subunits. In contrast, the α6, β2, and β4 nAChR subunits were not sensitive to Aβ~1--42~ competition ([@B97]). Although the authors speculated that the interactions occurred at the neuronal cell surface because the incubation period was relatively short, the fact that interactions were insensitive to β subunits suggests a significant association of lynx1 with individual α subunits or non-pentameric receptors, since only α7 subunits from this list have been shown to form homopentamers. These interactions are likely to occur beneath the membrane surface, consistent with the reported interaction of lynx1 with nAChR dimers in the endoplasmic reticulum ([@B73]). Conversely, when Aβ~1--42~ was used as the bait in pull-down experiments, it also pulled down all nAChRs tested, and lynx1 could compete at α7 and β2 subunits. Such findings are in accordance with the results of previous studies, which reported that Aβ~1--42~ can bind α7, α4β2, and α4α5β2 receptors ([@B16]; [@B104]; [@B51]). These results indicate that lynx1 and Aβ~1--42~ bind at similar sites on nAChRs. Although Aβ~1--42~ is thought to bind at the orthosteric binding site, it is possible for two peptides to bind at different sites and still provide orthosteric hindrance to receptor binding. If the lynx1 and Aβ~1--42~ interactions are significant *in vivo*, lynx1 may exert protective effects against the pathological progression of AD ([@B97]), highlighting the need for further studies on the entire receptor complex ([@B99]). In support of this, the toxic effect of Aβ~1--42~ in primary neuronal culture was reduced in the presence of ws-lynx1 ([@B97]). This notion is further supported by previous studies that have demonstrated the protective effects of lynx1 in neuronal health ([@B66]; [@B46]). Importantly, in the AD mouse model (3xTg AD), a reduction of lynx1 protein of 10% in the cortex was observed ([@B97]), suggesting a link between lynx1 and AD pathology. Thus, further studies are required to elucidate the role of Aβ~1--42~ in normal and disease states ([@B48]).

Lynx2/Lypd1
-----------

The existence of multiple lynx family members is advantageous in that it allows for better spatial or temporal control over the cholinergic system since each exhibits varying expression patterns in different circuits. For instance, lynx1 and lynx2 exhibit complementary and non-overlapping expression patterns (e.g., hippocampal CA3 for lynx1 and CA1 for lynx2) ([@B64]; [@B14]; [@B96]). The lynx2 gene expression also is enriched in well-described anxiety pathways, such as the amygdala and prefrontal cortex, which lends itself as a modulator of anxiety ([@B96]). Characteristic of the three-looped structure of the ly6/uPAR super family ([@B14]), the lynx2 protein binds to and suppresses the activity of nAChRs ([@B96]; [@B106]). *In vitro* immunoprecipitation experiments have demonstrated that lynx2 forms stable complexes with α7, α4β2, and α4β4 nAChRs ([@B96]; [@B106]). Co-expression of lynx2 and α4β2 leads to faster desensitization kinetics in response to acetylcholine ([@B96]) and a shift in the EC~50~ for acetylcholine ([@B96]), nicotine, and epibatidine ([@B106]) in the presence of lynx2. The presence of lynx2 also decreases the expression of α4β2 at the cell surface, suggesting a potential mechanism for the decreased response to agonists ([@B106]). There is also evidence that the lynx2 protein can blunt nicotine-induced upregulation of α4β2 ([@B106]). Lynx2-null mutant mice (lynx2KO) exhibit increased sensitivity to nicotine within the medial prefrontal cortex when compared to wild-type controls ([@B96]). These data suggest that ligand sensitivity is altered in the presence of lynx2, and that lynx2 also acts to inhibit the activity of nAChRs. The functional consequences of lynx2 removal include increased anxiety-like behaviors across several paradigms of anxiety, as well as reduced social interaction, suggesting that lynx2KO can be established as a robust mouse models of anxiety. Further studies into the removal of nAChR inhibition in lynx2KO mice are underway in order to determine the role of lynx2 in regulating specific nAChR subtypes *in vivo*. These studies underscore the importance of fine tuning the cholinergic system in a spatially controlled manner. The anxiety response includes a set of physiological changes that occur in response to a perceived threat. In the short term, this response is adaptive and helps defend against the threatening situation, but if the response is not regulated properly, it can lead to the development of anxiety disorders and significantly impact quality of life. Thus, lynx2 may play an important role in limiting or regulating the function of its cognate receptors to respond adaptively in circuits mediating anxiety-like behavior.

Slurps
======

The Ly6/uPAR superfamily members discussed thus far are a part of the subfamily composed of membrane-bound GPI-anchored proteins. The other subfamily is composed of non-GPI anchored proteins ([@B1]). The non-GPI anchored proteins are secreted and can exert a wide array of functions ([@B1]; [@B20]; [@B11]; [@B58]). SLURP-1 and SLURP-2 proteins represent two of these secreted, hormone-like cholinergic peptides of the ly6/uPAR superfamily ([@B1]; [@B11]). SLURP proteins are found in the cytoplasm and function widely in non-neuronal cells, regulating growth and finely tuning the cell cycle ([@B69]; [@B45]). While SLURP proteins also largely target nAChRs, SLURP-2 can also interact with muscarinic receptors ([@B60]). Most studies on SLURP function utilize recombinant or synthetic human SLURP proteins, as there are several methodological issues in obtaining the protein, such as an inability to obtain adequate amounts from natural sources, problems with production systems, and issues with protein folding ([@B59]).

SLURP-1 is expressed in keratinocytes, where its presence modifies ACh signaling and epidermal homeostasis during cutaneous inflammation ([@B20]; [@B11]); in primary sensory neurons in the dorsal horn of the spinal cord ([@B69]); in airway epithelial cells, where its presence stimulates ciliary beating and decreases airway inflammation ([@B70], [@B71]); and in corneal and ocular tissue ([@B93]). Such studies have demonstrated the role of SLURP-1 in Mal de Meleda keratoderma ([@B20]), nociception ([@B69]), asthma ([@B70], [@B71]), and pro-inflammatory conditions of the ocular surface ([@B93]). Consistent with these studies, the SLURP-1KO mouse displays a palmoplantar keratoderma phenotype ([@B2]).

Studies using recombinant human SLURP-1 (rSLURP-1) are detailed in [Table 1](#T1){ref-type="table"}. Data for similar experimental conditions differed among some studies, likely due to the use of different recombinant versions. Taken together, the evidence suggests that SLURP-1 functions as an allosteric modulator of α7 nAChRs ([@B11]; [@B71]; [@B58], [@B59], [@B55]; [@B17]). SLURP-1 can be immunoprecipitated and co-localized with α7 nAChRs ([@B59], [@B55]). Further studies have indicated that SLURP-1 does not compete with α-btx in oocytes or cause any changes in function on its own (i.e., without the presence of Ach as a ligand), suggesting an allosteric mode of action ([@B11]; [@B59]; [@B17]). There is conflicting data on the role of SLURP-1, which has been shown to both increase and decrease the E~max~, and to alter and not alter the EC~50~ ([@B11]; [@B59]; [@B17]).

###### 

SLURP and nAChR studies.

  SLURP                   Functional Effect                                                                                       Tag                                           Study
  ----------------------- ------------------------------------------------------------------------------------------------------- --------------------------------------------- --------
  rSLURP-1 human          Increase in E~max~ Shift to left of EC~50~                                                              C-terminal myc tag N-terminal HA tag          [@B11]
  rSLURP-1                N/A                                                                                                     N-terminal Flag, C-terminal GPI               [@B69]
  rSLURP-1                Suppresses cytokine production                                                                          N-terminal MBP tag                            [@B71]
  rSLURP-1                Competes with α-bgtx at AChBPs but not at α7 nAChRs, decrease in E~max~, no change in EC~50~            N-terminal Met                                [@B59]
  sSLURP-1                No α-btx competition at α7 nAChRs or AChBP                                                              Chemical peptide synthesis of human SLURP-1   [@B17]
  rSLURP-2                Reduces cell number, competes with epi and nic binding, partially competes with α-btx binding           Mature SLURP cleaved from His-SUMO            [@B5]
  rSLURP-2 and rSLURP-1   Reduces cancer cell number (colorectal)                                                                 N-terminal Met                                [@B58]
  rSLURP-2                SLURP-2 increases cytokine production in NHEK cells                                                     N-terminal FLAG epitope-tagged                [@B68]
  rSLURP-2                Decreases α7 currents except at low \[SLURP-2\]. Increases keratinocyte growth, binds multiple nAChRs   N-terminal Met                                [@B59]
  rSLURP-2 and rSLURP-1   May decrease growth in five of six α7-expressing cell lines                                             N-terminal Met                                [@B55]

Although such findings remain controversial, highlighting the need for characterization standards, further evidence suggests that SLURP-1 can also mediate inhibition of human α3β4, α4β4, and α3β2 nAChRs, as well as human and rat α9α10 nAChRs ([@B17]). The relevant data were derived from synthetically generated SLURP-1 (sSLURP-1), which exhibits similar structural yet different functional features when compared to rSLURP-1 ([@B17]). For instance, α-btx binding is not influenced by sSLURP-1 in torpedo membranes (muscle type nAChRs) or AChBP from either *A. Californica* or *L. Stagnalis*, whereas rSLURP-1 can compete with α-btx binding in torpedo membranes and AChBP from *L. Stagnalis*, although such findings were not observed at α7^∗^ nAChRs ([@B91]; [@B59]). Functionally, sSLURP-1 exerts no effect on α7^∗^ nAChR responses in oocytes. When the α7 component was potentiated by a PAM in mammalian, chaperone co-transfected Neuro-2A cells, however, high doses of agonist were associated with alterations in the E~max~ of epibatidine. In such experiments, calcium-sensitive dyes were used to measure activity indirectly. In oocyte expression systems, sSLURP-1 exerts more robust inhibitory effects on α3β4 nAChRs, although effects can also be observed at α4β4 and α9α10 nAChRs. Based on the accumulated evidence, researchers have speculated that sSLURP-1 acts as a "silent" negative allosteric modulator, exerting its effects only when the nAChR is in the open state ([@B17]). Despite structural similarities (e.g., differences in the sequence of the N-terminal methionine only), rSLURP-1 and sSLURP-1 need to be tested side by side in the same assay in order to understand potential functional differences, highlighting the need for strict compound characterization standards if results are to be reproducible and transferable ([@B17]).

SLURP-2 is also an endogenous modulator of nAChRs with 10 cysteine residues and a 28--34% amino acid homology with Ly6 family members ([@B101]; [@B69]; [@B80]). Historically, the LYNX1 gene was thought to give rise to both lynx1 and SLURP-2 due to alternative splicing, but recent evidence suggests that the genes are in close proximity but under the control of different transcription units ([@B68]; [@B54]). SLURP-2 differs from both SLURP-1 and lynx1 in that it has an overall negative charge ([@B60]). Compared to SLURP-1, SLURP-2 (also studied via rSLURP2, see [Table 1](#T1){ref-type="table"}) immunoprecipitates with several nAChR subtypes (α3-α7, β2, and β4) ([@B60]) and competes more efficiently with epibatidine than nicotine ([@B5]). SLURP-2 has been shown to interact with mAChRs in an heterologous CHO overexpression system ([@B60]). Confirmation of pull down of native complexes in tissue or genetic confirmation to verify this finding will be informative. SLURP-2 is expressed in human epidermal and oral keratinocytes ([@B5]; [@B69], [@B68]), and in various tissues throughout the body, including epithelial tissue, the stomach, duodenum, esophagus, thymus, cervix, and uterus ([@B101]). Additional studies have indicated that SLURP-2 is upregulated in psoriatic lesional skin and in atopic dermatitis after a stress response, demonstrating its role in regulating stress-related cytokines in the skin ([@B101]; [@B80]; [@B68]). The SLURP-2 KO mouse model also exhibits a palmoplantar skin disease phenotype ([@B4]). Both SLURP-1 and SLURP-2 can inhibit growth in cancer cell lines, suggesting an anticancer potential for these genes ([@B58], [@B55]). However, overall, SLURP-2 acts in opposition to SLURP-1 to prevent apoptosis ([@B5]; [@B60]).

Prostate Stem Cell Antigen (Psca)
=================================

Prostate stem cell antigen is a GPI-anchored cell surface protein localized on lipid rafts ([@B86]; [@B89]). Although PSCA was originally characterized as a gene upregulated in prostate cancer, it is also expressed in the mammalian ([@B44]; [@B77]) and avian brain ([@B38]), and is up-regulated 70% in the cortex of AD patients ([@B44]). Affinity purification studies have demonstrated that PSCA forms a stable complex with the α4 nAChR subunit but not the α7 subunit in the human temporal cortex ([@B44]). However, its expression in the choroid plexus is worth noting since it is predicted to play a role in cell differentiation and proliferation in epithelial tissues ([@B77]). In one previous study, PSCA exerted an inhibitory effect on cell death induction in the chick ciliary ganglion via α7-containing nAChRs ([@B38]). Furthermore, [@B44] revealed that PSCA decreases nicotine-induced ERK phosphorylation in PC12 cells and is dysregulated in the frontal cortex of patients with Alzheimer's disease, highlighting the potential role of PSCA in pathologies that alter cognitive function.

Lypd6
=====

Another family member, lypd6, is highly expressed in the brain and spinal cord of mice and humans ([@B12]; [@B109]). Lypd6 regulates nicotinic receptor activity by enhancing Ca^+2^ currents through α/β-heterodimers in mice ([@B12]). Lypd6 forms complexes with α3, α4, α5, α6, α7, β2, and β4 nAChR subunits and competes with α-btx for binding α7 subunits ([@B6]). However, previous studies have also reported that blockade of α7 with α-btx and methyllycaconitine does not affect the modulation of nicotine-induced currents by lypd6 ([@B12]). In contrast to the expression of lynx1 in parvalbumin cells, lypd6 is selectively expressed in somatostatin interneurons in cortical layers 5 and 6 of visual cortex region V1 ([@B12]).

The function of lypd6 has been demonstrated in several model systems. For example, in PC12 cells, a soluble version of lypd6 completely inhibits nicotine-induced phosphorylation of ERK, which is an important pathway activated during plasticity induction. In addition, decreases in nicotine-induced currents can be observed when water-soluble lypd6 is applied to hippocampal slices ([@B6]). In lypd6 overexpression studies, mice have demonstrated an increase in sensitivity to nicotine and behavior consistent with an increase in cholinergic tone, such as locomotor arousal, hypoalgesia, and pre-pulse inhibition of the acoustic startle response ([@B12]). Furthermore, lypd6 KO mice exhibit decreased baseline levels of anxiety-like behavior in two-independent behavioral assessments (i.e., elevated plus maze and marble burying tests) ([@B7]). Taken together, these results suggest that lypd6 plays a role in the negative modulation of nAChRs. Lypd6, however, also contains a Nxl motif, which allows it to bind LRP5/6, a member of the Wnt signaling pathway ([@B110]), and therefore some of the phenotypes may be mediated by the Wnt coreceptor, low density lipoprotein receptor-related protein 6 LRP5/6.

Lypd6b/Lypd7
============

Lypd6b, a member with large sequence similarity to lypd6, modulates nAChRs in a subtype-specific manner, and is expressed in glutamatergic neurons of the deep layer of the mammalian visual cortex ([@B13]). Studies involving *Xenopus* oocytes have demonstrated that lypd6b displays isoform selectivity for inhibiting nAChR-mediated currents through α3β4 nAChRs; however, its presence does not alter α7 subtype-mediated currents ([@B76]). Furthermore, whole-cell recordings have revealed that lypd6b selectively reduces nAChR-mediated currents through α3β4, indicating that modulation of the receptor may occur at the α-α interface ([@B76]). The subtype selectivity and stoichiometry of lypd6b indicate that this prototoxin plays a highly specialized and complex role in nAChR modulation. Lypd7 was cloned from a human testis library, and is primarily expressed in the testes, prostate, stomach, and lung ([@B72]).

Ly6h
====

In a previous *in vitro* study involving HEK cells expressing α7 nAChRs, a calcium-based FRET assay was used to determine the relative effect of a number of co-transfected ly6 proteins. To minimize receptor desensitization, the cells were treated with a positive allosteric modulator, PNU-120596, to allow for steady-state over kinetic measurements. The results indicated that there was a shift to the right of nicotine or epibatidine-evoked α7 responses when co-expressed with ly6h, similar to the shifts observed for lynx2 ([@B84]). Ly6h also caused a reduction in the maximal response and surface expression of α7 nAChRs, suggesting a role for ly6h in receptor trafficking and gating. Prior to this study, the ly6 antigens, which are primarily expressed outside the brain, were not implicated in nAChR regulation. Ly6h has also been shown to influence α4β2 nAChRs in a similar FRET assay, although the effects of ly6h on nAChR trafficking were too pronounced to calculate a reliable EC~50~ in these studies ([@B106]). Interestingly, ly6h exerted no effects when co-expressed with α4β2 nAChRs in pull-down studies in HEKtsa or on desensitization rates of ACh-evoked responses in oocytes, in contrast to the significant effects observed for lynx2 ([@B96]). Differences in the heterologous systems or tagged proteins may have influenced these results.

In studies involving cells expressing α4β2 nAChRs, although there was a decrease in response to epibatidine by over 50% in the presence of lynx2 or ly6h, less pronounced effects were observed when to ly6e and ly6g6d were present. Such studies have revealed that ly6c1, ly6a, ly6c2, and lypd2 do not modulate α4β2 receptor activity. Furthermore, ly6a does not co-immunoprecipitate, change α4β2 expression at the surface, or interfere with nicotine-mediate up-regulation of α4β2 receptors ([@B106]).

Ly6g6e
======

A relatively uncharacterized ly6 family member, ly6g6e, exhibits differences in function and mechanism from other members. Ly6g6e forms a complex with α4β2 nAChRs, and its presence potentiates rather than suppresses these receptors ([@B106]). Evidence suggests potentiation occurs due to direct modulation by ly6g6e at the cell surface. Cleaving the GPI anchor results in a loss of ly6g6e potentiation ([@B106]). Additional studies have indicated that ly6g6e can slow the desensitization of nAChRs ([@B106]). The potential mechanisms displayed by other family members, such as alterations in receptor expression at the cell surface or changes in nAChR ion selectivity, are unlikely, as ly6g6e does not alter the number of receptors at the membrane, and its effects persist in the absence of extracellular calcium ([@B106]). Ly6g6e expression has been detected in the hippocampus, cortical neurons, and in the midbrain ([@B106]). Based on its expression patterns and interactions with α4β2 nAChRs, which represent the main nAChRs contributing to nicotine addiction ([@B23]), ly6g6e may be involved in nicotine reward. Further studies are required to verify this possibility. The differential effects of ly6g6e on nAChRs demonstrate the diverse mechanisms of action present within the superfamily ([Supplementary Table 1](#SM1){ref-type="supplementary-material"}).

Preferential Prostate and Testes Expression (Pate)-M and Pate-B
===============================================================

Preferential prostate and testes expression proteins conform to three-fingered protein/ly6/urokinase-type plasminogen activator receptor (uPAR) domains that shape three-fingered proteins in a manner similar to that of the prototoxins discussed above. Three human PATE genes (PATE-M, PATE-DJ, and PATE-B) have been identified and have demonstrated effects on nicotinic receptor function ([@B53]). Two (hPATE-B and mPATE-C) enhance ACh-evoked net charge in oocytes expressing the homomeric α7 nAChR, while one (mPATE-P) reduces ACh-evoked net charge in oocytes expressing the α4β2 heteromeric nAChR ([@B53]).

Other Members of the Family
===========================

The ly6/uPAR superfamily continues to expand as more genes are characterized. Furthermore, interesting functions have been noted for members in invertebrate species, and 35 family members have been cloned from *Drosophila*, including *Coiled*, *Boudin* ([@B36], [@B35]), and *Sleepless* ([@B47]). Interestingly, the protein bou is expressed in salivary glands and can incorporate into other cells, indicating a possible non-cell autonomous role.

Prototoxin Binding Sites on nAchRs
==================================

Once the co-crystals of prototoxins and nAChRs have been identified, researchers should aim to determine the relevant binding sites, and whether these are associated with orthosteric or allosteric effects. The functional properties of prototoxins effects on nAChR function, such as desensitization and recovery from desensitization, although the effect of the GPI-anchored proteins on receptor trafficking, assembly, and stoichiometry may also account for these effects. Various reports have commented on the ability of prototoxins to compete on nAChRs with ligands that bind at the active site, such as nicotine, epibatidine, and α-btx ([@B56]; [@B17]; [@B7]). Thus, differences in receptor types and the ligands used must be carefully considered ([@B107]). An exogenously applied prototoxin that exerts modulatory effects on receptor function without competing with ligands provides support for allosterism.

While α-btx competition and nicotinic receptor upregulation studies have indicated that prototoxins may be involved in orthosteric interactions ([@B57], [@B60]; [@B106]), they are generally considered to be allosteric modulators ([@B40]; [@B100]; [@B59]). Prototoxins that potentiate ligand-elicited currents can be regarded as positive allosteric modulators if they require acetylcholine or an agonist to open the receptor. Studies regarding the effect of lynx2 on nicotine-mediated up-regulation have suggested that lynx2 and nicotine operate at the same point in the receptor maturation pathway, potentially competing for binding at the ligand binding site. However, there are mechanisms that may allow for effects on receptor maturation that do not involve direct interaction at the same site on the receptor. Mutant cycle analyses have confirmed that actions at one part of the receptor can be communicated even across long distances from the receptor to the active site ([@B31]).

There is a low-potency, high-efficacy, tertiary binding site on the α4: α4 interface of (α4)~3~(β2)~2~ nAChRs that can potentiate activation of the receptor by ACh ([@B42]). The presence of a third ligand at the two classical sites can lead to receptor transitions, detectable in both E~max~ and changes in the Hill slope. The authors contend that this is indicative of a pre-activational state similar to that of the benzodiazepine binding site on the GABA receptor ([@B42]). At present, it remains unknown how prototoxins interact with this third, low-potency site. [@B60] have suggested that SLURP-2 acts as a co-ligand for α7 nAChRs by priming it at low SLURP-2 concentrations. Although they postulate that SLURP-2 can work in concert with a single-bound ACh by binding at the orthosteric site, this only occurs at low SLURP-2 concentrations and is not accompanied by evident changes in Hill slope ([@B60]). However, it would be interesting if a similar third binding site for agonists, with an ability to interact with prototoxins, were found to exist for α7 nAChRs. The differences in functional effects between rSLURP-1 and sSLURP-1 are most likely explained by the mode of synthesis vs. expression in *E. coli* vs. mammalian/insect cells and structural differences in nAChR types. With larger modulatory proteins, it is likely that both allosteric and orthosteric effects can be observed at nAChRs.

The Case for *In Vivo* Tests of Prototoxin Binding in the Body and Brain
========================================================================

To our knowledge, there have been no unbiased investigations of prototoxin receptors to isolate every interacting partner of a prototoxin. This leaves open the possibility that prototoxins may bind to other classes of receptors outside of nAChRs *in vivo*. All tests of receptor interaction, whether positive (e.g., nAChRs ([@B40]; [@B84]), mAChRs ([@B56], [@B60]), LRP6 ([@B110]), shaker potassium channels ([@B105]), or negative (e.g., glutamate, 5-HT3, etc.) have used either heterologously expressed receptor complexes, or have added the prototoxin to brain tissue. Only one study has isolated native complexes from the mammalian brain. In this study, β2^∗^ nAChR-containing receptors and lynx1 were identified using pull down studies from the mouse brain ([@B75]), while ws-lynx1, SLURP-1 and SLURP-2 has been successfully mixed with human brain tissue to pull down multiple nAChR subtypes ([@B59],[@B60]; [@B97]). To support the *in vivo* interaction studies, a lynx1KO phenotype was ameliorated by crossing these mice into mutant mice null for α7 and β2 nAChR genes ([@B66]). These *in vivo* studies provide an important biological context for the interactions observed within *in vitro* systems.

It should be noted that, even within brain tissues, many of these interactions may take place in the cytoplasm, and may therefore be independent of gating functions on the mature receptor pentamers at the cell surface. Receptor number can be reduced via the co-expression of prototoxin ([@B84]; [@B106]; [@B30]), suggesting an effect on receptor retention or slowing of receptor maturation. Additional studies have indicated that the receptor complexes that escape to the cell surface may form complexes prototoxins ([@B73]; [@B84]; [@B106]), retaining their modulatory functions. Except in limited cases, however ([@B106]; [@B30]), prototoxins have been demonstrated to retain functional effects even when they have been cleaved from the GPI-anchor using PI-PLC, suggestive of stronger intracellular functions. Antibodies against these proteins that can discriminate cellular localization and surface vs. intracellular prototoxins are greatly needed to determine which of the multiple possible effects demonstrated thus far occur within the brain. Clearly, the interactions between prototoxins and their cognate receptors can be long-term, exerting varied (e.g., assembly and gating) and multiple (e.g., orthosteric and allosteric) effects throughout the life-time of a receptor ([Supplementary Table 1](#SM1){ref-type="supplementary-material"}).

Promise of Prototoxin Studies for Therapeutic Development
=========================================================

Numerous studies have indicated that α4β2 and α7 nAChRs may represent targets for the treatment of various neurological and neuropsychiatric disorders ([@B32]; [@B82]; [@B8]; [@B85]; [@B10]; [@B74]; [@B103]; [@B18]). Among the limitations in successfully targeting nAChRs are the sequence similarities amongst the individual subunits, as well as their widespread expression patterns. The elucidation of prototoxin function has potentially important consequences from a therapeutic perspective. The receptor/prototoxin complexes in specific tissues provide unique interfaces with more restricted expression profiles, allowing for more specific therapeutic modulation than the receptor alone. Furthermore, most prototoxins exhibit multiple binding specificities, which may be advantageous for regulating a multiplicity of nAChR subtypes in concert which govern a pathway, circuit, or biological function. Rather than targeting multiple nAChR subunits with multiple therapeutics, naturally evolving regulators of physiologically relevant functions, via allosteric interventions on nAChRs, may provide safer and more specific effects. Such an approach would enable a much more specific level of cholinergic regulation than can be achieved by targeting ACh levels or nicotinic receptor subtypes alone.

Methods
=======

Molecular Phylogenetic Analysis
-------------------------------

Reference protein sequences were obtained from GenBank or BLAST. Evolutionary analyses were conducted in MEGA7 (Molecular Evolutionary Genetics Analysis) ([@B50]). Protein sequences obtained from GenBank were aligned using the MUSCLE algorithm within MEGA7 program. The evolutionary history was inferred by using the Maximum Likelihood method based on the Dayhoff matrix based model ([@B94]). Several substitution models were considered prior to selecting the Dayhoff model using MEGA7 model selection algorithms. Initial trees for the heuristic search were obtained automatically by applying Neighbor-Join and BioNJ algorithms to a matrix of pairwise distances estimated using a JTT model, and then selecting the topology with superior log likelihood value. The final bootstrap consensus tree inferred from 500 replicates ([@B19]) was taken to represent the evolutionary history of the taxa analyzed. Branches corresponding to partitions reproduced in less than 50% bootstrap replicates were collapsed.
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α-btx

:   alpha-bungarotoxin

5-HT~3A~R

:   5-hydroxytryptamine receptors

Aβ

:   beta-amyloid

AChBP

:   acetylcholine binding protein

DHβE

:   dihydro-β-erythroidine

EC~50~

:   Effective concentration, 50%

E~max~

:   efficacy, maximal response

ERK

:   Extracellular Signal-regulated Kinase-1

GPI

:   glycosylphosphatidylinositol

HEK

:   human embryonic kidney

HS

:   high sensitivity

KO

:   knockout

LS

:   low sensitivity

ly6

:   lymphocyte antigen 6

Lynx

:   Ly6/neurotoxin

MEGA

:   Molecular Evolutionary Genetics Analysis

nAChR

:   nicotinic acetylcholine receptor

NMR

:   nuclear magnetic resonance

PATE

:   prostate and testes expression

PI-PLC

:   phosphoinositide phospholipase C

PSCA

:   prostate stem cell antigen

rSLURP

:   recombinant SLURP

SLURP1

:   secreted ly6/uPAR-related protein 1

SLURP2

:   secreted ly6/uPAR-related protein 2

sSLURP

:   synthetic SLURP

uPAR

:   urokinase-type plasminogen activator receptors

V1

:   visual cortex area 1

WTX

:   weak neurotoxin.
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